RE:RE:RE:RE:RE:9 more sitesEnriqueSuave ... I concur. NMIBC approval, plus Ph. 1b data on GBM and NSCLC and COVID-19 would clearly bring our market valuation much higher. Easily. 10B$US+.
NSCLC is the #1 cancer in both US and Canada (and in many other countries).
NSCLC and GBM are extremely hard-to-beat cancers, so their extremely low survival rates. Any life extension by only couple of months always end up obtaining Breakthrough Therapy designation and Accelerated Approval, Priority Review, etc ... So imagine tumor destruction! Any major efficacy % would have a huge price tag and would put PDT/PDC on the map.
COVID-19 (therapeutic and prevention) would also have a 1B$+ valuation. But so far, we know little about that. But if the potential to protect and/or destroy concretizes, and given that NML is involved in all this, chances are high that it will work, given the tiny TLD-1433 doses required to destroy the envelop of these types of viruses.
The heavy lifting that TLT has done up until now has to be recognized. And will soon, backed by clinical data.
_____________________
enriquesuave - (1/3/2023 11:30:17 PM)
RE:RE:RE:RE:9 more sites
I just checked and see that Endocyte buyout happened in Oct. 2018 and the drug approval was 3.5 years later in March of 2022. If we get AA, then a good chance we get bought out with an approved drug and while 3 PH1 trials are in place, GBM, NSCLC and COVID.. $2.1 Billion will be cheap. IMHO